PNPLA6

Across TCGA pan-cancer cohorts, PNPLA6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PNPLA6 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PNPLA6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PNPLA6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where PNPLA6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	1.000	0.809	.012	15	view →
LUAD	OS	Tertile	All	0.481	0.912	.009	13	view →
UCEC	DFS	Quartile	All	0.773	1.000	.011	6	view →
HNSC	DFS	Median	All	0.355	0.854	.030	6	view →
PDAC	OS	Median	IV	0.836	0.491	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PNPLA6–CCRCC (DFS)

Open the CCRCC breakdown →